PLUR
NASDAQPluri Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News25/Ratings0
News · 26 weeks220%
2026-03-012026-08-23
Mix1490d
- SEC Filings5(36%)
- Other4(29%)
- Insider4(29%)
- M&A1(7%)
Latest news
25 items- INSIDERDirector Shorrer Doron was granted 31,569 shares, increasing direct ownership by 474% to 38,228 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Manieu Alexandre Weinstein was granted 180,000 shares, increasing direct ownership by 1,671% to 190,769 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- SECPluri Inc. filed SEC Form 8-K: Other Events8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic InvestmentEver After Foods secures an additional $2 million strategic investment supporting ongoing platform development and commercialization activities. HAIFA, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri"), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its majority-owned food-tech portfolio company, Ever After Foods Ltd. (EAF), an industrial technology company developing an open manufacturing platform for cultivated-protein, has acquired Fishway BV, a Belgium-based biotechnology company specializing in
- PREver After Foods Acquires Fishway to Expand Integrated Food Production Technology PlatformHAIFA, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Ever After Foods (EAF) today announced the strategic acquisition of Fishway, representing an important milestone in the company's long-term strategy to expand its industrial protein manufacturing platform through the integration of complementary technologies and scientific capabilities. Following a successful technology collaboration validating the compatibility of the two platforms, the acquisition adds a portfolio of aquatic cell lines, expertise in animal-component-free (ACF) media, and a highly experienced scientific team, strengthening Ever After Foods' industrial protein manufacturing platform while shortening development cycles and ac
- PRPluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UKUK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a market with an estimated size of ~$900 million annually, and strengthens the foundation for broader international expansion HAIFA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. ("Cellav"), has successfully completed the cosmetic regulatory registration and notification process in the U
- SECPluri Inc. filed SEC Form 8-K: Other Events8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%HAIFA, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today provided an update on the cumulative investment and ownership position of its Chairman, Mr. Alejandro Weinstein. Over the past year, Mr. Weinstein has invested more than $17 million in Pluri through a series of investments, including a $1.25 million advance investment made in June 2026 pursuant to an Advance Subscription Agreement, as disclosed in the Company’s Form 8-K filed on June 22, 2026. Mr. Weinstein currently owns more than 30% of the Company’s issued and outstanding shares. His growing com
- SECPluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Pluri Inc. (0001158780) (Filer)
- INSIDERNew insider Shorrer Doron claimed ownership of 13,628 shares (SEC Form 3)3 - Pluri Inc. (0001158780) (Issuer)
- INSIDERDirector Manieu Alexandre Weinstein was granted 641 shares, increasing direct ownership by 10% to 6,925 units (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- SECPluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products ListingTwo regenerative aesthetic and longevity products, with clinically validated ingredients, are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. ("Cellav"), has completed the development and U.S. cosmetic product listings of two flag
- SECPluri Inc. filed SEC Form 8-K: Other Events8-K - Pluri Inc. (0001158780) (Filer)
- SECSEC Form 10-Q filed by Pluri Inc.10-Q - Pluri Inc. (0001158780) (Filer)
- INSIDERDirector Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)4 - Pluri Inc. (0001158780) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Pluri Inc.SCHEDULE 13D/A - Pluri Inc. (0001158780) (Subject)
- SECSEC Form DEFA14A filed by Pluri Inc.DEFA14A - Pluri Inc. (0001158780) (Filer)
- SECSEC Form DEF 14A filed by Pluri Inc.DEF 14A - Pluri Inc. (0001158780) (Filer)
- SECPluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementHAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company's largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026. This additional investment follows Mr. Weinstein's prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further
- SECPluri Inc. filed SEC Form 8-K: Other Events8-K - Pluri Inc. (0001158780) (Filer)
- PRPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentExpands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China's growing cell therapy market and supports cross-border partnerships HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we", "our" or "us") (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces that the China National Intellectual Property Administration (CNIPA) has gra
- SECSEC Form 10-Q filed by Pluri Inc.10-Q - Pluri Inc. (0001158780) (Filer)
- SECPluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Pluri Inc. (0001158780) (Filer)
PLUR FAQ
4 questionsWhere does PLUR stock trade?
Pluri Inc. (PLUR) is listed on NASDAQ.What sector and industry is PLUR in?
Pluri Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to PLUR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare PLUR side-by-side with any of them on Quantisnow.How can I track PLUR on Quantisnow?
Quantisnow aggregates Pluri Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLUR to receive live email and push alerts on every new disclosure.